|Awarded On||February 19, 2014|
|Title||Developing Two Clinical Proof of Concept Drugs that Inhibit a Novel Cancer Cell Target|
|Program||Product Development Research|
|Award Mechanism||Company Formation|
|Institution/Organization||Iterion Therapeutics Inc.|
|Principal Investigator/Program Director||Rahul Aras|
|Cancer Sites||Colorectal, Leukemia|
Beta Cat Pharmaceuticals specializes in developing novel cancer drugs that attack molecular targets never before addressed clinically. Our first drug, BC2059, inhibits the beta catenin pathway and represents a major breakthrough. Many cancers have abnormal activation of this pathway but despite much industry effort, no drugs have been developed previously that address it. Beta Cat has succeeded by attacking a novel target in the pathway. BC2059 has very low toxicity but is highly effective at killing tumor cells.
We first will test the drug in colorectal carcinoma and in myelodysplastic syndrome, an orphan drug indication. We also have a promising second generation program that we hope to mo...